Ugn-501

Phase 1

Ugn-501 is one of 3 therapeutic programs targeting Bladder (Urothelial, Transitional Cell) Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Bladder (urothelial, Transitional Cell) CancerNot yet recruiting

Bladder (urothelial, Transitional Cell) CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Bladder (urothelial, Transitional Cell) Cancer

#DrugCompanyPhaseTrials

TARA-002

PProtara Therapeutics

Phase 3

1 2

NDV-01 (sustained-Release Gemcitabine-Docetaxel)

RRelmada Therapeutics, Inc.

Phase 3

1 3

Ugn-501

UUroGen Pharma Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Not yet recruiting

Bladder (urothelial, Transitional Cell) Cancer

NCT07725796

Clinical

Trials by Indication[1]

Bladder (Urothelial, Transitional Cell) Cancer1 trial

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Not yet recruiting·UUroGen Pharma Ltd.·Phase 1·NCT07725796·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ugn-501. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ugn-501. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — UroGen Pharma Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUroGen Pharma Ltd.

Ugn-501

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Bladder (Urothelial, Transitional Cell) Cancer1 trial

References

Drug Info

Quick Facts

Related News